Declining measles vaccination isn't a problem confined to the US. Last month, the World Health Organization (WHO) and UNICEF ...
An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial, leaving them sifting through the data for signals of efficacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback